Business Context and Reporting Period
This Form 8-K was filed by Vanda Pharmaceuticals Inc. on November 19, 2015. The report discloses a significant legal event involving the company's intellectual property rights related to its product Fanapt.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal proceeding and does not contain financial performance data.
Material Changes
The material change reported is the initiation of a patent infringement lawsuit. On November 19, 2015, Vanda Pharmaceuticals Inc. filed a lawsuit in the United States District Court for the District of Delaware against Lupin Limited and Lupin Pharmaceuticals, Inc. (collectively, "Lupin").
Guidance, Outlook, and Risks
- Legal Action: The lawsuit alleges that Lupin infringed U.S. Patent No. 9,138,432 (the "432 Patent") and U.S. Patent No. 8,586,610 (the "610 Patent") by submitting an Abbreviated New Drug Application (ANDA) for a generic version of Fanapt.
- Patent Expiration Dates: The '432 Patent is set to expire in September 2025, and the '610 Patent is set to expire in November 2027.
- Requested Relief: Vanda is seeking a permanent injunction to prevent Lupin from manufacturing, using, selling, importing, or distributing generic versions of Fanapt prior to the expiration of the asserted patents.
- Risks: The outcome of this litigation is uncertain and could impact the company's ability to maintain market exclusivity for Fanapt.
Investor Verification Checklist
- Verify the status of the lawsuit against Lupin Limited and Lupin Pharmaceuticals, Inc. in the District of Delaware.
- Confirm the validity and scope of U.S. Patent No. 9,138,432 and U.S. Patent No. 8,586,610.
- Monitor the FDA's response to Lupin's Abbreviated New Drug Application (ANDA) for generic Fanapt.
- Assess the potential financial impact of a generic entry before September 2025 or November 2027.